QPS, a global contract research organisation headquartered in the US, has opened a second preclinical research facility in Taipei, Taiwan. The 2,793-square-foot facility will facilitate a research expansion into additional toxicology studies and a newly launched capability in pharmacology studies.

The new facility will give QPS significant additional flexibility in study scheduling and additional space to grow the existing toxicology business and to build the new pharmacology unit.

Designed to ensure that the utmost care is taken with all toxicology and pharmacology studies, this new research facility boasts well equipped, fully accredited animal centers and a state-of-the-art pharmacology unit. Initially, the centre will focus on augmenting the current multi-species capabilities in wound healing models, with pharmacology services in irritable bowel disease (IBD), non-alcoholic steatohepatitis (NASH) and atopic dermatitis. The team will be ready to conduct these studies in a variety of species in early 2023.

QPS has hired Dr Mei-Ling Hou, PhD to lead the new pharmacology department. Hou joins QPS from the Department of Pharmacology and Toxicology at the Institute for Drug Evaluation Platform, Development Center for Biotechnology (DCB).  Dr. Hou's expertise will strongly propel the growth and development of this new pharmacology service.